Revolution Medicines

58 articles with Revolution Medicines

• Revolution Medicines to Host Science Talk Webcast Highlighting Learnings from Recent Preclinical and Clinical Studies of RAS Inhibitors

  6/10/2021

  Revolution Medicines, Inc., a clinical-stage precision oncology company developing targeted therapies to inhibit frontier targets in RAS-addicted cancers, announced that it will host a Science Talk webcast to highlight learnings from recent preclinical and clinical studies of RAS inhibitors.

• Revolution Medicines to Participate in Goldman Sachs 42nd Annual Global Healthcare Conference

  6/2/2021

  Revolution Medicines, Inc., a clinical-stage precision oncology company developing targeted therapies to inhibit frontier targets in RAS-addicted cancers, announced that the company will participate in the upcoming Goldman Sachs 42nd Annual Global Healthcare Conference.

• Revolution Medicines to Participate in Cowen 2nd Annual Virtual Oncology Innovation Summit

  5/18/2021

  Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company developing targeted therapies to inhibit frontier targets in RAS-addicted cancers, today announced that the company will participate in the upcoming Cowen 2 nd Annual Virtual Oncology Innovation Summit. Steve Kelsey, M.D., president, research and development, will be the featured speaker in a fireside chat at the event.

• Revolution Medicines Reports First Quarter 2021 Financial Results and Update on Corporate Progress

  5/10/2021

  Continued Advancement and Enrollment of Multiple RMC-4630 RAS Companion Inhibitor Combination Studies; Initiated Clinical Evaluation of RMC-5552

• Revolution Medicines Highlights Slate of Diverse Board of Directors Nominees for Upcoming 2021 Annual Shareholder Meeting

  5/3/2021

  Flavia Borellini, Ph.D., Distinguished Precision Oncology Drug Development Leader, Joins Existing Board Members Elizabeth McKee Anderson and Neil Exter as Class I Director Nominees

• Revolution Medicines Announces Dosing of First Patient in Phase 1/1b Clinical Study of RMC-5552 in Patients with Advanced Solid Tumors

  4/21/2021

  Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted therapies to inhibit frontier targets in RAS-addicted cancers, today announced dosing of the first patient in a multicenter Phase 1/1b clinical trial evaluating RMC-5552, the company’s investigational first-in-class bi-steric mTORC1 inhibitor as a monotherapy

• Revolution Medicines Announces Six Presentations at the American Association for Cancer Research Annual Meeting 2021

  3/11/2021

  Presentations Highlight Continued Progress Across Expanded R&D Pipeline of RAS(ON) Inhibitors and RAS Companion Inhibitors

• Revolution Medicines to Participate in Upcoming Investor Conferences - Mar 09, 2021

  3/9/2021

  Revolution Medicines, Inc., a clinical-stage precision oncology company developing targeted therapies to inhibit frontier targets in RAS-addicted cancers, announced that the company will participate in two upcoming investor conferences.

• Revolution Medicines Reports Fourth Quarter and Year-End 2020 Financial Results and Update on Corporate Progress

  3/2/2021

  Revolution Medicines, Inc., a clinical-stage precision oncology company focused on developing targeted therapies to inhibit frontier targets in RAS-addicted cancers, announced its financial results for the fourth quarter and year ended December 31, 2020, and provided a corporate update.

• Revolution Medicines to Participate in Digital RAS-Targeted Drug Discovery Summit and Upcoming Investor Conferences

  2/18/2021

  Steve Kelsey, M.D., President, Research and Development, to Present its Pioneering RAS(ON) Inhibitors and Participate in Panel Discussion

• Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

  2/8/2021

  Revolution Medicines, Inc. (Nasdaq:RVMD) today announced the closing of an underwritten public offering of 6,666,666 shares of common stock at a public offering price of $45.00 per share, before underwriting discounts and commissions.

• Revolution Medicines Announces Pricing of Upsized $260.9 Million Public Offering of Common Stock - Feb 04, 2021

  2/4/2021

  Revolution Medicines, Inc. announced the pricing of its underwritten public offering of 5,797,101 shares of common stock at a public offering price of $45.00 per share, before underwriting discounts and commissions.

• Revolution Medicines Announces Proposed Public Offering of Common Stock - Feb 01, 2021

  2/1/2021

  Revolution Medicines, Inc. announced that it has commenced an underwritten public offering of 4,000,000 shares of common stock.

• Revolution Medicines to Provide R&D Pipeline Update, Including Progress of RAS(ON) Inhibitor Programs, During Presentation at 39th Annual J.P. Morgan Healthcare Conference

  1/5/2021

  Revolution Medicines, Inc., a clinical-stage precision oncology company developing targeted therapies to inhibit frontier targets in RAS-addicted cancers, announced that Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman, will deliver a corporate presentation as part of the 39th Annual J.P. Morgan Healthcare Conference.

• Revolution Medicines Reports Third Quarter 2020 Financial Results and Update on Corporate Progress

  11/12/2020

  Recommended Phase 2 Dose and Schedule Selected for Further Evaluation of RMC-4630 as Monotherapy and RMC-4630 plus Cobimetinib Combination

• Revolution Medicines Reports Progress and Expansion of Combination Strategy with RMC-4630 as Therapeutic Backbone for RAS-Addicted Cancers

  10/24/2020

  Company Also Announces New Clinical Collaboration with AstraZeneca to Study RMC-4630 in Combination withan Emerging AstraZeneca Asset Targeting KRASG12C

• Revolution Medicines to Present Interim Data at ENA 2020 from Phase 1b/2

  10/12/2020

  Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company developing targeted therapies to inhibit frontier targets in RAS-addicted cancers, today announced that interim data from the company’s ongoing Phase 1b/2 clinical trial (RMC-4630-02) evaluating the combination of RMC-4630 and cobimetinib (Cotellic ® ) will be reported in an oral presentation in a plenary session at the upcoming EORTC-NCI-AACR 32 nd Sy

• Revolution Medicines Reports Preclinical Tumor Regressions Induced by First-in-Class KRAS-G12D(ON) Inhibitors

  9/16/2020

  Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted therapies to inhibit frontier targets in RAS-addicted cancers, today reported data demonstrating that its first-in-class KRASG12D(ON) inhibitors induced tumor regressions in a preclinical model of human pancreatic cancer carrying an oncogenic KRASG12D mutation.

• Revolution Medicines to Present at the H.C. Wainwright 22nd Annual Global Investment Conference

  9/9/2020

  Revolution Medicines, Inc., a clinical-stage precision oncology company focused on developing targeted therapies to inhibit frontier targets in RAS-addicted cancers, announced that Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman, will deliver a corporate presentation as part of the H.C. Wainwright 22nd Annual Global Investment Conference.

• Revolution Medicines to Participate in 2nd Annual RAS-Targeted Drug Development ConferenceCompany’s Scientific Leadership to Deliver Presentations, Participate in Panel Discussion and Co-Lead Workshop During Digital Event

  9/8/2020

  Revolution Medicines, Inc., a clinical-stage precision oncology company focused on developing targeted therapies to inhibit frontier targets in RAS-addicted cancers, announced that the company will participate in the upcoming 2nd Annual RAS-Targeted Drug Development Conference being held virtually September 14-16, 2020.